FDMT

4D Molecular Therapeutics (FDMT)

4D Molecular Therapeutics Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:FDMT

1 2 3 4 5 6 7 8 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/05/10	05:22	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:FDMT	4D Molecular Therapeutics Inc
2024/05/10	05:05	GlobeNewswire Inc.	4DMT Reports First Quarter 2024 Financial Results and Operational Highlights	NASDAQ:FDMT	4D Molecular Therapeutics Inc
2024/05/07	21:00	GlobeNewswire Inc.	4DMT to Participate in Upcoming Investor Conference	NASDAQ:FDMT	4D Molecular Therapeutics Inc
2024/05/01	21:00	GlobeNewswire Inc.	4DMT Announces Presentations at ARVO 2024 Annual Meeting	NASDAQ:FDMT	4D Molecular Therapeutics Inc
2024/03/28	21:00	GlobeNewswire Inc.	4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis	NASDAQ:FDMT	4D Molecular Therapeutics Inc
2024/03/04	22:00	GlobeNewswire Inc.	4DMT to Participate in Upcoming Investor Conferences	NASDAQ:FDMT	4D Molecular Therapeutics Inc
2024/03/01	08:01	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:FDMT	4D Molecular Therapeutics Inc
2024/03/01	07:15	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:FDMT	4D Molecular Therapeutics Inc
2024/03/01	06:12	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:FDMT	4D Molecular Therapeutics Inc
2024/03/01	06:05	GlobeNewswire Inc.	4DMT Reports Full Year 2023 Financial Results and Operational Highlights	NASDAQ:FDMT	4D Molecular Therapeutics Inc
2024/02/22	07:41	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:FDMT	4D Molecular Therapeutics Inc
2024/02/15	10:51	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:FDMT	4D Molecular Therapeutics Inc
2024/02/15	06:37	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:FDMT	4D Molecular Therapeutics Inc
2024/02/14	22:43	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:FDMT	4D Molecular Therapeutics Inc
2024/02/13	11:04	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:FDMT	4D Molecular Therapeutics Inc
2024/02/13	10:22	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:FDMT	4D Molecular Therapeutics Inc
2024/02/12	22:00	GlobeNewswire Inc.	4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium™ 2024	NASDAQ:FDMT	4D Molecular Therapeutics Inc
2024/02/10	06:56	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:FDMT	4D Molecular Therapeutics Inc
2024/02/09	06:50	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:FDMT	4D Molecular Therapeutics Inc
2024/02/09	06:23	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:FDMT	4D Molecular Therapeutics Inc
2024/02/09	06:22	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:FDMT	4D Molecular Therapeutics Inc
2024/02/08	10:32	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:FDMT	4D Molecular Therapeutics Inc
2024/02/08	09:42	Edgar (US Regulatory)	Form 3/A - Initial statement of beneficial ownership of securities: [Amend]	NASDAQ:FDMT	4D Molecular Therapeutics Inc
2024/02/07	13:27	GlobeNewswire Inc.	4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock	NASDAQ:FDMT	4D Molecular Therapeutics Inc
2024/02/06	07:27	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:FDMT	4D Molecular Therapeutics Inc
2024/02/06	06:35	Edgar (US Regulatory)	Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers	NASDAQ:FDMT	4D Molecular Therapeutics Inc
2024/02/06	06:05	GlobeNewswire Inc.	4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock	NASDAQ:FDMT	4D Molecular Therapeutics Inc
2024/02/04	07:00	GlobeNewswire Inc.	4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD	NASDAQ:FDMT	4D Molecular Therapeutics Inc
2024/01/29	22:00	GlobeNewswire Inc.	4DMT to Host Corporate Webcast to Discuss Interim Data from Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 in Wet AMD Patients with Severe Disease Activity & High Treatment Burden	NASDAQ:FDMT	4D Molecular Therapeutics Inc
2024/01/26	06:59	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:FDMT	4D Molecular Therapeutics Inc